Expertise in
6
conditions

Dr. Elias I. Obeid

Oncology
Envision Hospital Medicine
1945 Route 33, 
Neptune, NJ 
Accepting New Patients
Referral may be required
Before you request
Expertise in
6
conditions
Envision Hospital Medicine
1945 Route 33, 
Neptune, NJ 

Overview

Elias Obeid is an Oncologist practicing medicine in Neptune, New Jersey.

Dr. Obeid is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

Dr. Obeid is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 33 peer reviewed articles and participating in 6 clinical trials. Dr. Obeid is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in IL

Board Certifications

American Board Of Internal Medicine

Fellowships

University of Chicago Hospitals

Hospital Affiliations

Hackensack University Medical Center
St Joseph's University Medical Center Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Envision Hospital Medicine
1945 Route 33, Neptune, NJ 7753.
Other Locations
The Cancer Center at Totowa
225 Minnisink Road, Totowa, NJ 7512.

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug, Other
Study Drugs: Mifepristone, Nab-Paclitaxel
Study Phase: Phase 2
Genetic Evaluation of Men (GEM)
Genetic Evaluation of Men (GEM)
Enrollment Status: Terminated
Publish Date: April 29, 2025
Intervention Type: Other
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Biological, Drug
Study Drugs: Paclitaxel, Pelareorep, Avelumab
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

33 Total Publications

What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?
What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?
Journal: The Journal of surgical research
Published: December 05, 2023
Similar Doctors
Expertise in
37
conditions
Dr. Michele L. Donato
Oncology | Hematology
Expertise in
37
conditions
Dr. Michele L. Donato
Oncology | Hematology
Referral may be required
Before you request

HMH - John Theurer Cancer Center - Neptune

19 Davis Avenue, Floor 2, 
Neptune, NJ 
 (0.1 miles away)
732-897-3530
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michele Donato is an Oncologist and a Hematologist practicing medicine in Neptune, New Jersey. Dr. Donato is highly rated in 37 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Colonoscopy. Dr. Donato is board certified in American Board Of Internal Medicine. Dr. Donato is currently accepting new patients.

Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (39.4 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (38.7 miles away)
929-343-3624
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Tap is an Oncologist practicing medicine in New York, New York. Dr. Tap is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization. Dr. Tap is currently accepting new patients.

Frequently Asked Questions about Dr. Elias I. Obeid

How do I make an appointment with Dr. Elias I. Obeid?

You can book an appointment with Dr. Elias I. Obeid by calling their office at 732-776-2963. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elias I. Obeid a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elias I. Obeid is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elias I. Obeid specialize in?

While Dr. Elias I. Obeid is a Oncology, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Elias I. Obeid participate in research or clinical trials?

Yes. Dr. Elias I. Obeid has published 33 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Elias I. Obeid's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elias I. Obeid accept my insurance?

Dr. Elias I. Obeid accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 732-776-2963 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Obeid's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile